

1 **Comprehensive analysis across *SMN2* excludes DNA methylation as an epigenetic**
2 **biomarker for spinal muscular atrophy**

3

4 M.M. Zwartkuis^{1,2}, J.V. Kortoos¹, D. Gommers^{1,2}, M.G. Elferink², I. Signoria¹, J. van der
5 Sel^{1,2}, P.J. Hop^{1,4}, R.A.J. Zwamborn¹, R. Geene⁶, J.W. Green¹, H.W.M. van Deutekom², W.
6 van Rheenen¹, J.H. Veldink¹, F. Asselman¹, R.I. Wadman¹, W.L. van der Pol¹, G.W. van
7 Haaften^{2*}, E.J.N. Groen^{1*}

8

9 ¹Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center
10 Utrecht, Utrecht, the Netherlands; ²Department of Genetics, University Medical Center Utrecht, Utrecht,
11 the Netherlands; ⁴Department of Translational Neuroscience, UMC Utrecht Brain Center; ⁵Center for
12 Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; ⁶Utrecht Sequencing
13 Facility, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands;
14 ⁷Oncode Institute, Utrecht, the Netherlands.

15

16 *These authors contributed equally.

17

18 Correspondence: UMC Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
19 g.vanhaaften@umcutrecht.nl, +31 8875 67747 (GWvH); e.j.n.groen-3@umcutrecht.nl, +31
20 8875 73834 (EJNG).

21

22 **Abstract**

23

24 Spinal muscular atrophy (SMA) is a severe neurodegenerative disease caused by defects in
25 the survival motor neuron 1 (*SMN1*) gene. The wide variability in SMA severity is partially
26 explained by an inverse correlation with copy number variation of the second human *SMN*
27 gene (*SMN2*). Nevertheless, significant variability in severity and treatment response remains
28 unexplained, prompting a search for accessible biomarkers that could explain and predict this
29 variability. DNA methylation of *SMN2* has been proposed as one such biomarker, but
30 comprehensive evidence and analyses are lacking. Here, we combined long-read nanopore
31 sequencing with targeted bisulfite sequencing to enable high-resolution analysis of *SMN2*-
32 specific methylation patterns. We observed tissue-specific variation in DNA methylation across
33 the entire 30 kb *SMN2* gene in 29 patients analyzed by long-read nanopore sequencing,
34 identifying variable methylation patterns in the promoter, introns, and 3' UTR. Subsequent
35 targeted analysis of these regions by bisulfite sequencing of blood-derived DNA in 365 SMA
36 patients showed no association between *SMN2* methylation and disease severity or treatment
37 response, excluding blood methylation patterns as predictive biomarkers. However, we
38 discovered significant age-associated variation in *SMN2* methylation, particularly in intron 1
39 and the 3' UTR, highlighting DNA methylation as a possible modifier of SMN expression during
40 development and aging. Our approach provides a broadly applicable strategy for detailed but
41 cost-effective and high-throughput characterization of DNA methylation in other genes and
42 diseases, including complex genetic regions.

43

44 **Keywords:** spinal muscular atrophy; survival motor neuron gene; DNA methylation; long-read
45 sequencing; bisulfite sequencing.

46 Introduction

47

48 Spinal muscular atrophy (SMA) is a devastating neurodegenerative disease characterized by
49 progressive muscle weakness and atrophy that may cause infantile death or severe childhood
50 disability. The incidence is approximately 1 in 6,000-10,000 live births [1]. SMA is caused by
51 homozygous deletion or mutation of the *survival motor neuron 1 (SMN1)* gene, which results
52 in insufficient production of the critical and ubiquitously expressed SMN protein [2]. While SMA
53 patients lack a functional *SMN1* gene, they retain one or more copies of the highly similar
54 *SMN2* gene. The *SMN2* gene can partially compensate for the loss of *SMN1*, but its ability to
55 do so is limited by alternative splicing that excludes exon 7, producing a truncated and
56 unstable form of the SMN protein [3–5]. The number of *SMN2* gene copies, ranging from one
57 to six in patients with SMA, inversely correlates with disease severity, with higher copy
58 numbers associated with milder phenotypes [6,7]. However, this relationship is not absolute,
59 and significant variability in clinical presentation exists even among patients with the same
60 *SMN2* copy number [6,8]. Additionally, the expression of SMN is strongly developmentally
61 regulated through unknown mechanisms, with high pre- and neonatal expression followed by
62 a reduction later in life [9,10]. Finally, treatment response to the three currently available gene-
63 targeted therapies varies between patients with equal *SMN2* copy numbers [11,12]. These
64 observations suggest that factors beyond *SMN2* copy number may influence SMN protein
65 expression and SMA outcomes.

66 One potential source of this variability may lie in the epigenetic regulation of *SMN2*, as
67 has often been hypothesized [7,11,13–16]. DNA methylation is a key epigenetic mechanism
68 that can influence gene expression without altering the underlying DNA sequence [17].
69 Previous studies have identified differential methylation patterns in the *SMN2* promoter region
70 between SMA patients with varying disease severities, suggesting that DNA methylation may
71 influence *SMN2* expression [18,19]. Furthermore, the methyl-CpG-binding protein MECP2 has
72 been shown to interact with methylated sites in the *SMN2* promoter, potentially regulating *SMN*
73 gene activity [18,20]. Several studies investigated genome-wide differential DNA methylation

74 in SMA patients, however with limited sample sizes [21,22]. While these initial findings are
75 intriguing, the existing literature on *SMN2* methylation in SMA is limited, often focusing on a
76 small number of CpG sites within the promoter region and in small patient cohorts. Our overall
77 understanding of variation in DNA methylation in patients with SMA therefore remains limited.

78 To fully elucidate the role of DNA methylation in the regulation of *SMN2*, a more
79 comprehensive analysis across the entire gene is warranted. In this study, we therefore aimed
80 to provide a detailed characterization of DNA methylation patterns across *SMN2* in a large
81 cohort of patients with SMA, using a combination of long-read nanopore sequencing and
82 targeted bisulfite sequencing. We identified lowly methylated CpG sites in the *SMN2* promoter,
83 the transcription site of the long non-coding RNA *SMN-AS1*, several intronic regions, and the
84 3' UTR of *SMN2*, with tissue-specific differences. No association between DNA methylation
85 and disease severity or treatment response was found, ruling out DNA methylation as an
86 epigenetic biomarker of SMA. DNA methylation was significantly associated with age at the
87 *SMN2* 3'UTR and intron 1, suggesting these changes might be involved in the regulation of
88 SMN expression during development and aging.

89

90 **Results**

91

92 *Nanopore sequencing reveals extensive variation in DNA methylation across SMN2 and*
93 *copy-specific differential methylation between SMN2 haplotypes*

94 To comprehensively explore DNA methylation across *SMN2* in SMA patients, we determined
95 CpG methylation status from nanopore sequencing data from 10 blood samples and 22
96 fibroblast samples from 29 patients with varying *SMN2* copy numbers and SMA types (**Table**
97 **S1**) [23]. We aligned the sequencing reads to *SMN1* by masking *SMN2* and phased the reads
98 into two to five haplotypes as described previously [23]. We analyzed DNA methylation per
99 patient and per *SMN2* haplotype (**Fig. 1A**) and visualized the methylation percentage per CpG
100 site in a heatmap (**Fig. 1B**). In addition to low methylation of the promoter region, low
101 methylation was also observed in the transcription site of the lncRNA *SMN-AS1* [14], the 3'
102 UTR and various other, intronic regions of *SMN2*. Hierarchical clustering (**Fig. 1B**) and
103 principal component analysis (PCA, **Fig. 1C**) showed that methylation data from fibroblast and
104 blood clustered separately, as expected based on previous reports showing variation in DNA
105 methylation between tissues [24]. Fifty-eight sites were differentially methylated ($p_{\text{adj}} < 0.01$)
106 between blood and fibroblasts (**Fig. 1B** and **1D**). Because of this, subsequent analyses were
107 performed separately for each tissue. When exploring a possible correlation between DNA
108 methylation and disease severity by SMA type in this small group of samples, no differentially
109 methylated sites were found (**Fig. 1E-F**). We and others previously identified multiple single
110 nucleotide variants (SNVs) that can be used to study the genomic environment of individual
111 *SMN* copies and serve as markers of gene conversion [23,25] and used these insights to next
112 study DNA methylation per *SMN* haplotype (**Fig. S1A**). When comparing *SMN2* haplotypes
113 with *SMN1* environment SNVs to those with *SMN2* environment SNVs (**Fig. 1G**), we found
114 five differentially methylated CpG sites in blood and seven in fibroblasts ($p_{\text{adj}} < 0.01$), of which
115 four overlapped (**Fig. 1H-I, Fig. S1**). However, most of these are at known SNV positions [23]
116 (**Fig. S1B-C**), and these differences are therefore likely caused by a nucleotide variant in the
117 CpG site, resulting in a non-CpG site (**Fig. 1J**). Non-CpG methylation is possible in humans,

118 but its properties and functions are not well known [26,27]. Hence, it was not included in the
119 methylation calling algorithms of this study (**Methods**). Interestingly, although based on a
120 limited number of observations, one of the differentially methylated sites in blood
121 (chr5:71381516, promoter region) was not a known SNV site, indicating a possible association
122 between gene environment and methylation status. In summary, ONT sequencing allowed us
123 to study DNA methylation across the entire *SMN2* gene and led us to identify several regions
124 of interest (ROIs) for further analysis in a larger cohort.

125

126 *DNA methylation in the SMN2 gene can be determined by targeted bisulfite sequencing*

127 To investigate whether variation in DNA methylation identified by ONT sequencing was linked
128 to disease severity or treatment response, we performed targeted bisulfite sequencing on DNA
129 isolated from blood from 365 SMA patients (**Fig. S2, Table 1, Table S2-3**). Per patient, we
130 pooled 18 amplicons containing the ROIs identified by ONT sequencing (**Fig 2A, Table S4**),
131 15 of which were successfully sequenced by barcoded Illumina sequencing (>100x read depth
132 in at least 90% of patients). We included only CpG sites that were mapped on the intended
133 targets with at least 100x read depth and excluded potential SNV sites (**Fig. S3A**). Median
134 read depth per CpG site was 3,014-37,870x and for every CpG site, 95-100% of the patients
135 had a methylation call (**Fig. S4A-B**). For nine patients, both nanopore and bisulfite methylation
136 data was available; methylation percentages showed high correlation between data types
137 (Spearman's $R=0.77$, $p<2.2e-16$, **Fig. S4C**). Heatmap visualization of methylation percentage
138 per CpG site illustrated that most variation was present in the promoter region and 3'UTR. We
139 performed hierarchical clustering of patients and found that clustering was mostly based on
140 variation in intron 1 and the 3' UTR of *SMN2* (**Fig. 2B**). We performed further dimensionality
141 reduction of the dataset by filtering out CpG sites with little variation in methylation percentage
142 (standard deviation <5%) and CpG sites with high correlation (Spearman $R>0.9$), resulting in
143 57 sites for further analysis and statistical testing (**Fig. S3A-B**).

144

145 *DNA methylation significantly correlates with age at 22 CpG sites across SMN2*

146 To explore whether DNA methylation was associated with baseline patient characteristics –
147 such as sex and age – we performed PCA, excluding patients with uncommon genotypes:
148 carriers of an *SMN1* copy with loss-of-function variants or the positive modifier c.859G>C in
149 *SMN2*. Male and female groups completely overlapped (**Fig. 3A**), whereas age group clusters
150 only partly overlapped (**Fig. 3B**). Differential methylation analysis did not yield differentially
151 methylated sites between male and female patients (**Fig. 3C**). In contrast, DNA methylation
152 was significantly associated with age at 15 sites including three collapsed sites ($p_{\text{adj}} < 0.01$, **Fig.**
153 **3D**), corresponding to 22 CpG sites in total. Interestingly, DNA methylation percentage
154 increased with age at one site (promoter region) but decreased at all other significantly
155 associated sites in intron 1, the 3' UTR and the lncRNA *SMN-AS1* sequence (**Fig. 3E**). As this
156 association implies that age may be a confounding variable, we corrected for it in our
157 subsequent statistical analyses. The sites associated with age did not contain common
158 nucleotide motifs (**Fig.S5**). Altered DNA methylation may affect binding of CCCTC-binding
159 factor (CTCF), which may in turn affect 3D genome organization and alternative splicing [28–
160 30]. However, CTCF binding site motifs (CTCF_HUMAN.H11MO.0.A on
161 hocomoco11.autosome.org [31]) did not overlap with any of the age-related CpG sites in
162 *SMN2* [32] (**Fig. S6**). To investigate whether age-associated changes in *SMN2* DNA
163 methylation affect *SMN2* mRNA expression, we made use of previously generated expression
164 data from whole blood [8]. We found that *SMN2-FL* RNA expression was significantly
165 associated with age in patients with three copies of *SMN2*, but not in patients with four copies
166 of *SMN2* (**Fig. S7A**), possibly because this group did not include patients younger than 6 years
167 old and the sharpest decline of SMN expression happens perinatally [9]. We tested whether
168 there was an association between DNA methylation and *SMN2-FL* expression in patients with
169 three *SMN2* copies. An association can be observed between DNA methylation and *SMN2-*
170 *FL* expression at most CpG sites associated with age, where methylation appeared to be
171 higher in patients with higher *SMN2-FL* expression (**Fig. S7B**), although these associations
172 were not statistically significant (**Fig. S7C**).

173

174 *No association between DNA methylation in SMN2 and disease severity or treatment*

175 *response*

176 To investigate whether DNA methylation was associated with disease severity or treatment
177 response, we first analyzed patients with genetic variants that potentially modify disease
178 severity separately. We found no association between DNA methylation and presence of
179 *SMN1* or the c.859G>C variant in *SMN2* (**Fig. S8**). Patients with these genotypes were
180 excluded from further analyses, since their phenotypes are likely affected by these genetic
181 variants. To test if DNA methylation was associated with *SMN2* copy number, we first
182 performed PCA that suggested there might be differences between copy number groups (**Fig.**
183 **4A**). However, this observation was likely confounded by age as mentioned above, since
184 patients with lower *SMN2* copy number are often sampled at younger ages than patients with
185 higher copy number. Indeed, when correcting for age, none of the tested sites were
186 significantly associated with *SMN2* copy number (**Fig. 4C**). Similarly, no association was found
187 between DNA methylation and copy number of the *NAIP* gene (**Fig. S9A**), which has also
188 been suggested as a potential modifier of SMA, although inconclusively [13]. No significantly
189 differentially methylated sites were found for disease severity by SMA type (**Fig. 4B** and **4D**)
190 or age at onset (**Fig. S9B**). No differentially methylated sites were found when comparing SMA
191 types or ages at onset in patients with three or four *SMN2* copies separately (**Fig. S9C-F**). In
192 addition, we tested the differentially methylated CpG sites from previous work [19] specifically,
193 but did not replicate any of these associations in our cohort (**Fig. S10**). Finally, we compared
194 changes in the commonly used Hammersmith functional motor scale (HFMSE) scores of a
195 cohort of patients with three or four *SMN2* copies before and 1.5 years after nusinersen
196 treatment initiation (dHFMSE, n=111 **Fig. 4E**). Based on dHFMSE, patients were divided in
197 three treatment response groups: decline, stabilization, and increase. PCA did not show clear
198 clustering of these groups (**Fig. 4F**), and no CpG sites were significantly associated with
199 dHFMSE (**Fig. 4G**). These observations do not completely exclude the possibility that in
200 individual or rare changes in DNA methylation may still affect SMA outcomes. However, the
201 absence of associations between variation in *SMN2* DNA methylation and disease severity or

202 treatment response in these analyses excludes *SMN2* DNA methylation as an epigenetic
203 biomarker of SMA in blood.
204

205 Discussion

206

207 An important outstanding question in the SMA field is the absence of a clear correlation
208 between phenotype and genotype, even among patients with equal *SMN2* copy number.

209 Variation in DNA methylation of *SMN2* has long been hypothesized as a possible explanation
210 for this discrepancy [7,11,13–16]. Indeed, several previous studies suggested that variation in

211 DNA methylation could be a potential modifier of SMA [18,19], but these studies were limited
212 by technological possibilities and sample size, and comprehensive analyses of DNA

213 methylation across the complete *SMN2* gene in large SMA patient cohorts had not been done
214 previously. In this study, we addressed this issue by combining long-read nanopore

215 sequencing to first discover variability in DNA methylation across the complete *SMN2* gene in
216 a limited group of patients, followed by targeted bisulfite sequencing across the identified sites

217 in a large cohort of 365 SMA patients. We identified variable DNA methylation at multiple sites,
218 including the *SMN2* 3'UTR and the intronic transcription site of lncRNA *SMN-AS1*. DNA

219 methylation was significantly associated with age at all tested sites in intron 1 and the 3' UTR
220 of *SMN2*, and two CpG sites in the promoter and three CpG sites in the transcription site of

221 lncRNA *SMN-AS1*. However, DNA methylation was not significantly associated with *SMN2*
222 copy number, disease severity, treatment response, or *SMN2-FL* mRNA expression. In

223 summary, our results exclude variation in DNA methylation in *SMN2* as an epigenetic
224 biomarker of clinical SMA outcomes but highlight DNA methylation as a possible modifier of

225 SMN expression.

226

227 We did not identify methylation differences in the *SMN2* promoter between SMA types in
228 patients with three copies of *SMN2* as reported previously [19]. This previously reported

229 difference may have been observed due to a lower sample size (n=35 versus n=211 in our
230 study) or lenient multiple testing correction due to inclusion of a much smaller number of CpG

231 sites. Another previous study specifically investigated DNA methylation in a group of patients
232 with two *SMN2* copies and either SMA type 1 or SMA type 3. We were unable to replicate

233 these results as the number of patients with two *SMN2* copies in our cohort was limited. In
234 addition, the combination of two *SMN2* copies and SMA type 3 is extremely uncommon, and
235 it cannot be ruled out that the patients included in the previous study were carriers of rare
236 positive modifiers such as c.859G>C or c.835-44A>G, which were not commonly
237 characterized at the time that study was performed. We did not find association between DNA
238 methylation and disease severity in blood as accessible biomarker tissue, but DNA methylation
239 may still play a role in disease-relevant inaccessible tissues such as the spinal cord. Although
240 we did not find DNA methylation in blood measured before treatment initiation to be associated
241 with treatment response in this study, there is still the possibility that epigenetic marks might
242 be involved in the regulation of exon 7 inclusion during treatment [33]. Therefore, longitudinal
243 epigenetic studies may still hold promise for identifying additional targets to strengthen the
244 ability of splice modifiers to increase SMN expression.

245

246 In contrast to limited variability in DNA methylation in the *SMN2* promoter region, we observed
247 significant variation in the *SMN2* 3'UTR. Previous studies have associated 3'UTR methylation
248 of other genes with both increased gene expression [34–36], decreased gene expression [37–
249 42], or both [43,44]. Therefore, it is likely that 3'UTR DNA methylation can affect gene
250 expression in different ways for different genes, and through different mechanisms, such as
251 altered protein binding [45], alternative polyadenylation [46,47] or alternative splicing [41]. In
252 the *SMN* genes specifically, Marasco *et al.* showed that a nusinersen-like ASO promotes
253 chromatin-silencing mark H3K9me2, slowing down RNA polymerase II elongation and
254 inhibiting exon 7 inclusion [33]. Reduced DNA methylation in gene bodies is linked to
255 increased chromatin accessibility [48], and increased DNA methylation and H3K9 methylation
256 with heterochromatin [49]. Therefore, reduced DNA methylation at the 3' end *SMN2* could
257 potentially be associated with faster RNA polymerase II elongation and increased exon 7
258 inclusion. Although we identified no significant association between *SMN2-FL* expression and
259 DNA methylation in blood, further association analyses between DNA methylation and (long-

260 read) RNA sequencing in other tissues may indicate whether DNA methylation affects splicing
261 and expression of specific exons and isoforms of the *SMN* gene.

262

263 DNA methylation is associated with age across mammalian tissues, and this association can
264 be either positive or negative, varying per CpG site [50]. Our current study identified several
265 CpG sites, mostly located in intron 1 and the 3' UTR of *SMN2*, that were associated with age
266 in our patient cohort. For most sites, we observed that higher age was associated with reduced
267 levels of DNA methylation. A similar pattern was found in the *TARDBP* gene in human motor
268 cortex of healthy subjects and ALS patients, and accelerated DNA demethylation in ALS was
269 associated with earlier disease onset [41]. Therefore, it would be interesting to determine
270 whether age-related decrease of DNA methylation in *SMN2* is also present in healthy subjects.
271 Analyzing this in large control cohorts, however, is challenging as short-read sequencing of
272 bisulfite converted DNA samples does not allow to distinguish *SMN1* and *SMN2* in persons
273 that carry both genes in contrast to SMA patients who only carry copies of *SMN2*. This may
274 become possible in the future when long-read sequencing allowing haplotype-based analysis
275 becomes more routine and scalable. Previous research has shown that SMN protein levels
276 decline rapidly during the perinatal period in *post-mortem* spinal cord [9]. Similarly, *SMN*
277 mRNA and SMN protein expression have been reported to decrease with age in peripheral
278 blood mononuclear cells [10] but remain relatively stable in primary fibroblasts derived from
279 adult patients [10,51]. These findings highlight the potential differences in SMN requirements
280 between young children and adult patients, with potential implications for treatment
281 requirements. While infants and young children may benefit from therapies that maximize
282 SMN expression especially during the first few months of life, this may change in adulthood
283 when patients may have different needs in terms of maintaining sufficient SMN levels as they
284 age. The age-related changes in *SMN2* methylation patterns observed in our study could
285 represent an important consideration for the development of epigenetic therapies that aim to
286 modulate SMN expression across the lifespan. Although speculative, strategies based on the
287 use of catalytically inactive Cas9 (dCas9) fused to the catalytic domain of TET1 (TET1CD) for

288 demethylation [52] or the catalytic domain of DNA methyltransferase 3A (DNMT3A) to increase
289 methylation [53], could form a potential epigenetic therapeutic target for SMA.

290

291 **Conclusions**

292

293 We used nanopore long-read sequencing to reveal extensive variation in DNA methylation
294 across the *SMN2* gene, with low methylation levels observed not only in the promoter region
295 but also in the transcription site of *SMN-AS1*, the 3' UTR, and various intronic regions. With
296 targeted bisulfite sequencing of 365 SMA patients, no associations were found between DNA
297 methylation and sex, *SMN2* copy number, disease severity or treatment response, excluding
298 DNA methylation in *SMN2* as an epigenetic biomarker of clinical SMA outcomes. We
299 identified 22 CpG sites across *SMN2* where DNA methylation was significantly associated
300 with age, highlighting DNA methylation as a possible modifier of SMN expression during
301 development and aging.

302

303 **Methods**

304

305 *Study population*

306 We included 370 SMA patients from our single-center prevalence cohort study in the
307 Netherlands, as detailed in **Table 1 and Table S1-3**; 24 patients overlap between nanopore
308 and bisulfite sequencing datasets. The study protocol (09307/NL29692.041.09) was approved
309 by the Medical Ethical Committee of the University Medical Center Utrecht and was registered
310 in the Dutch registry for clinical studies and trials (<https://www.ccmo.nl/>). Written informed
311 consent was obtained from all adult participants, as well as from parents or guardians for
312 patients under 18 years of age. *SMN1*, *SMN2*, and *NAIP* copy numbers were quantified using
313 multiplex ligation-dependent probe amplification (MLPA) (MRC Holland, SALSA MLPA
314 Probemix P021 SMA Version B1) following the manufacturer's instructions
315 (<https://www.mrcholland.com/>). The clinical classification of SMA type was conducted based
316 on motor milestones and age at onset as previously described, with type 1 as non-sitters, type
317 2 as sitters, and type 3 and 4 as walkers [54]. To capture the broad genotypic and phenotypic
318 diversity within the SMA population, the study included patients with *SMN2* copy numbers
319 ranging from two to five, and SMA types ranging from 1b to 4. Whole blood samples were
320 collected in EDTA tubes for DNA extraction, and 3 mm dermal biopsies were obtained for the
321 generation of primary fibroblasts. For 111 patients with three or four *SMN2* copies and
322 receiving nusinersen treatment, Hammersmith Functional Motor Scale – Expanded (HFMSE)
323 scores were available that had been determined before treatment start and 1.5 years after
324 treatment initiation. For PCA, we stratified patients based on treatment response: decrease
325 for $dHFMSE \leq -3$; stabilization for $-3 < dHFMSE < 3$; increase for $dHFMSE \geq 3$ [55].

326

327 *DNA extraction and bisulfite conversion*

328 For bisulfite sequencing, DNA was extracted from whole EDTA blood with the BI chemagic
329 DNA Blood 4k kit (Revvity, CMG-1074). DNA concentration was quantified with the Quant-
330 iT™ 1X dsDNA BR Assay (Invitrogen, Q33267). Genomic Quality Number (GQN) was

331 determined with the Fragment Analyzer Genomic DNA 50kb Kit (Agilent, DNF-467). 500ng of
332 DNA was bisulfite-converted using the EZ-96 DNA Methylation-Lightning Kit (Zymo, D5033)
333 according to the manufacturer's instructions. Concentration of converted DNA was
334 measured with a spectrophotometer (Thermo Scientific, Nanodrop 2000) with the ssDNA
335 setting.

336

337 *Polymerase chain reaction for bisulfite amplicon sequencing*

338 Primers to amplify the top strand of bisulfite-converted DNA were designed with the Zymo
339 Bisulfite Primer Seeker (<https://zymoresearch.eu/pages/bisulfite-primer-seeker>) with default
340 options and intended product sizes of 450-550bp. Primers included a sequencing adapter-
341 compatible overhang (5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' to 5' end of
342 the forward primer, 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3' to 5' end of
343 the reverse primer). Primer sequences (Integrated DNA Technologies) and amplicon-specific
344 conditions are listed in **Table S4**. Eighteen PCRs were performed on each bisulfite-
345 converted patient DNA sample. Each 10uL PCR reaction contained 2.4μL PCR-grade water,
346 5μL KAPA HiFi HotStart Uracil+ ReadyMix (2X) (Roche, 7959052001), 0.3μL of each primer
347 (10μM), and a variable amount of DNA optimized for each reaction (**Table S4**). The PCR
348 was run using a Biorad T100 thermocycler (#1861096) with the following protocol: 95°C for 3
349 minutes; 36 cycles of 98°C for 30 seconds, annealing at variable temperatures for 15
350 seconds (ramp rate 0.5°C/s), followed by 72°C for 15 seconds (ramp rate 1.1°C/s); and a
351 final elongation at 72°C for 1 minute. All 18 amplicons were visualized on a 2% agarose gel
352 containing Sybr Safe (Fisher Scientific, #10328162) for a subset of eight randomly selected
353 samples and imaged on a Biorad ChemiDoc™ MP Imaging System (#12003154). Band
354 intensity was quantified with Fiji software (version 1.54). Relative band intensity was used for
355 determining the pooling ratio for amplicon pooling, e.g. a relative brightness of 2x resulted in
356 a pooling ratio of 0.5x. All 18 amplicons were pooled per patient and subsequently cleaned
357 with AMPure XP beads at a ratio of 0.65x to eliminate PCR reagents and small DNA
358 fragments. A subset of samples was run on the Agilent 2200 TapeStation (#G2965A) with

359 Agilent High Sensitivity D1000 ScreenTape (5067-5584) and High Sensitivity D1000
360 Reagents (5067-5585) to check for overamplification.

361

362 *Library preparation and Illumina sequencing*

363 A second PCR was performed on each patient sample containing 18 pooled amplicons to
364 attach Illumina DNA/RNA UD Indexes Sets A-D (Illumina, 20091654, 20091656, 20091658,
365 20091660) barcodes to the compatible overhangs that were included in the first PCR (see
366 above). Each 25 μ L PCR reaction contained 5.5 μ L PCR-grade water, 12.5 μ L NEBNext Q5
367 Hot Start HiFi PCR Master Mix (NEB, M0544L), 2.5 μ L of unique Illumina® DNA/RNA UD
368 Index, and 2.5ng of DNA in a volume of 2 μ L. The PCR was run in a Biorad T100
369 thermocycler with the following steps: 98°C for 30 seconds; six cycles of 98°C for 10
370 seconds followed by 65°C for 75 seconds; and a final elongation at 65°C for five minutes.
371 The PCR products were purified with AMPure XP beads at a ratio of 0.8x. A subset of
372 samples was measured on the Agilent 2200 TapeStation with Agilent High Sensitivity D1000
373 ScreenTape and High Sensitivity D1000 Reagents to check if the Illumina DNA/RNA UD
374 Indexes had successfully annealed. The concentration of a subset of individual samples was
375 measured with the Qubit dsDNA High Sensitivity kit (Thermo Fisher Scientific, #Q32854) kit
376 to check if concentrations were roughly equal, and all samples were pooled at equal volume.
377 The DNA concentration of the final pooled library was measured with the Qubit dsDNA High
378 Sensitivity kit. 785pM library with 2% PhiX Sequencing Control was loaded onto an Illumina
379 Nextseq2000 P1 flow cell and sequenced with 2x300bp paired-end read settings.

380

381 *Nanopore data processing*

382 Nanopore sequencing data was generated previously (**Table S1**)[23]; one patient was
383 excluded due to a partial deletion of *SMN1* exon 1-6, another patient was excluded due to
384 unavailability of clinical data. In summary, raw sequencing data was basecalled with Guppy
385 v6.1.2 with the SUP model (dna_r9.4.1_450bps_modbases_5mc_cg_sup.cfg) and mapped
386 to the T2T-CHM13 reference genome masked for a ~170kb region surrounding *SMN2* [23]. If

387 data from both blood and fibroblasts of the same patient was available, this data was not
388 merged. Polyploid haplotype phasing was performed with GATK and WhatsHap as
389 described previously [23]. Methylation calling was performed for full bam files and per-
390 haplotype bam files with modbam2bed v1.0 with options -e -m 5mC -r chr5:71375000-
391 71425000 --cpg. Methylation calls from forward and reverse strands were merged per CpG
392 site. Methylation percentage was calculated from modbam2bed output with the formula:
393
$$N_{\text{mod}} / (N_{\text{mod}} + N_{\text{can}}) * 100.$$

394

395 *Illumina data processing*

396 Bisulfite sequencing data was processed with the methylseq v2.6.0 workflow from nf-core
397 [56], including raw data QC with FastQC, adapter sequence and quality trimming (Phred<20)
398 with Trim Galore!, read alignment to the masked T2T-CHM13 reference genome [23] with
399 Bismark and extraction of methylation calls with Bismark. Default options were used, except
400 for: --unmapped, --skip_deduplication and --save_align_intermeds. For each sample, the
401 bismark.cov.gz file from the methylation_coverage output directory was loaded into R4.4.0
402 [57] and the data for all samples were merged into one dataset. Methylation percentage was
403 used directly from the cov.gz file. The data was filtered to only contain CpG sites that are
404 located on the intended amplicons and had a read depth (methylated reads + unmethylated
405 reads) of 100x or more. When the C or G of a CpG site was a known SNV position [25], it
406 was removed, to prevent any SNVs to be mistakenly interpreted as methylation changes,
407 since unconverted DNA was not sequenced. Additional data filtering was applied before
408 statistical testing with linear models, to reduce dimensionality: sites with little variation
409 between samples (methylation percentage standard deviation <5%) were removed, and
410 highly correlated sites with Spearman's $R > 0.9$ were treated as one site by averaging (**Fig.**
411 **S3**).

412

413 *Visualization and exploration of methylation data*

414 Methylation percentages were visualized per sample or per haplotype using the pheatmap
415 v1.0.12 package [58] in R v4.4.0. Row clustering was performed with the ward.D2 method
416 and Euclidian distance. PCA was performed with the function PCA from the FactoMineR
417 v2.11 package [59] followed by the function fviz_pca_ind from package factoextra v1.0.7
418 [60].

419

420 *DNA motif analyses*

421 The sequence surrounding the tested CpG sites (20bp upstream and 20bp downstream)
422 was extracted with bedtools v2.30.0. DNA binding motifs for CTCF were downloaded from
423 CTCF_HUMAN.H11MO.0.A on hocomoco11.autosome.org [31]. FIMO ([https://meme-](https://meme-suite.org/meme/doc/fimo.html)
424 [suite.org/meme/doc/fimo.html](https://meme-suite.org/meme/doc/fimo.html) [32]) was used to scan the *SMN1/2* gene sequence for CTCF
425 binding motifs. Sequence logos were generated using
426 <https://weblogo.threeplusone.com/create.cgi> [61].

427

428 *Statistics*

429 Required sample size was calculated in R4.4.0 using the pwr v1.3-0 package [62] using the
430 pwr.f2.test function. To detect a medium effect size (Cohen's $f^2=0.15$) [63] in a linear model
431 with a power of 80%, alpha of 0.01 and assuming 4 regression degrees of freedom
432 (corresponding to three covariates), a sample size of 115 is required. Differential methylation
433 analysis was performed using linear models in R4.4.0 with the following formula [64]:
434 `dependent_variable ~ independent_variable + covariates`; using methylation percentage as
435 dependent variable. For each independent variable (such as age at sampling or SMA type),
436 one formula was made per CpG site, thus one p-value was calculated for every CpG site
437 and corrected for multiple testing with the false discovery rate (FDR) method. Covariates
438 used were age at sampling in years (except when age was independent variable) [50,65],
439 sex [66], library size per *SMN* copy and GQN. Continuous independent variables such as
440 age at sampling were included in the model as numeric values, whereas factors with two
441 levels were converted to 0 and 1. Ordinal independent variables such as *SMN2* and *NAIP*

442 copy number were used as numeric values. SMA type was converted to numeric in the
443 following way before using it as independent variable: type 1 to 0, type 2 to 1, type 3 to 2 and
444 type 4 to 3. For testing concordance in ONT data, the data was divided into two groups due
445 to small sample size: less severe with three copies of *SMN2* and type 2b or less severe and
446 with four copies of *SMN2* and type 3b or less severe; more severe with three copies of
447 *SMN2* and type 2a or more severe and with four copies of *SMN2* and type 3a or more
448 severe. Similarly, we compared the less severe group versus the concordant and more
449 severe group taken together. Volcano plots were made by plotting the $-\log_{10}$ of the adjusted
450 p-value against the estimate of the regression coefficient belonging to the independent
451 variable for each CpG site. Results of all statistical tests including effect sizes for all CpG
452 sites are denoted in **Table S5**.

453

454

455 **Declarations**

456

457 *Ethics approval and consent to participate*

458 The study protocol (09307/NL29692.041.09) was approved by the Medical Ethical Committee
459 of the University Medical Center Utrecht and registered at the Dutch registry for clinical studies
460 and trials (<https://www.ccmo.nl/>). Written informed consent was obtained from all adult
461 patients, and from patients and/or parents additionally in case of children younger than 18
462 years old.

463

464 *Consent for publication*

465 Not applicable.

466

467 *Declaration of interests*

468 WvR has sponsored research agreements with Biogen and Astra Zeneca. JHV reports to
469 have sponsored research agreements with Biogen, Eli Lilly and Astra Zeneca. The other
470 authors declare no competing interests.

471

472 *Acknowledgements*

473 We thank the patients who participated in this study. This work was supported by grants from
474 Stichting Spieren voor Spieren (to WLvdP), the European Union's Horizon 2020 Research and
475 Innovation Program under the Marie Skłodowska-Curie grant (H2020 Marie Skłodowska-Curie
476 Actions) agreement no. 956185 (SMABEYOND ITN to WLvdP, EJNG) and Prinses Beatrix
477 Spierfonds (W.OB21-01 to EJNG). This project has received funding from the European
478 Research Council (ERC) under the European Union's Horizon 2020 research and innovation
479 programme (grant agreement n° 772376 - EScORIAL). We acknowledge the Utrecht
480 Sequencing Facility (USEQ) for providing sequencing service and data. USEQ is subsidized

481 by the University Medical Center Utrecht and The Netherlands X-omics Initiative (NWO project
482 184.034.019).

483

484 *Author contributions*


485 Conceptualization, MMZ, MGE, DG, EJNG, GWvH; experimental studies, MMZ, IS, JK, JG,
486 RG; bioinformatics and data analysis MMZ, MGE, DG, HWMvD, JvdS, RAJZ, PJH, WvR;
487 clinical data & patient material, FA, RIW, WLP; writing–original draft, MMZ, EJNG, GWvH;
488 writing–review, all; resources, EJNG, WLvdP; supervision, EJNG, JHV, WLvdP, GWvH;
489 funding acquisition, EJNG, GWvH, WLvdP.

490

491 *Data and code availability*

492 The datasets used and/or analyzed during the current study are available from the
493 corresponding author on reasonable request but are not publicly available due to privacy
494 restrictions. The code used for analyses in this study is available at:
495 https://github.com/ghaaften/SMA_DNA_methylation.

496



497

498 **Figure 1: DNA methylation varies extensively throughout the *SMN2* gene and varies**
 499 **between tissues.**

500 (A) Overview of sequencing and bioinformatics approaches in this study. Nanopore
 501 sequencing with adaptive sampling was performed on high molecular weight DNA of SMA
 502 patients. Reads were mapped to *SMN1* and phased into haplotypes as described previously

503 [23]. Methylation percentage per CpG site was determined per patient and per haplotype.

504 Created with Biorender.com.

505 (B) Heatmap of CpG DNA methylation in and around the *SMN2* gene (T2T-CHM13
506 chr5:71375000-71425000) in SMA patients with a homozygous *SMN1* deletion and one
507 patient with one copy of *SMN1* with a pathogenic mutation (indicated with an asterisk). Each
508 row represents one patient, each column represents one CpG site. Hierarchical clustering
509 with the ward.D2 method was performed on the rows. Patient characteristics are shown left
510 of the heatmap.

511 (C) Principal component analysis (PCA) of the methylation data from (B). Blood samples
512 (pink) cluster separately from fibroblast samples (orange).

513 (D) Differential methylation analysis of DNA methylation between fibroblasts (n=22) and
514 blood (n=10). 58 sites are differentially methylated between tissues ($p_{adj}<0.01$).

515 (E) Differential methylation analysis of DNA methylation between more severely (n=6) and
516 less severely (n=4) affected patients for blood samples. No differentially methylated sites
517 were found ($p_{adj}<0.01$).

518 (F) Differential methylation analysis of DNA methylation between more severely (n=10) and
519 less severely (n=8) affected patients for fibroblast samples. No differentially methylated sites
520 were found ($p_{adj}<0.01$).

521 (G) Schematic representation of haplotypes with *SMN1* environment SNVs and *SMN2*
522 environment SNVs.

523 (H-I) Volcano plot DNA methylation of haplotypes with *SMN1* environment SNVs versus
524 haplotypes with *SMN2* environment SNVs, for blood (H) and fibroblasts (I). Five differentially
525 methylated sites were found in blood and seven sites in fibroblasts. Sample sizes are as
526 indicated in (G).

527 (J) Schematic representation of a methylated CpG site, and likely consequences for
528 methylation if either the C or G changes to another nucleotide: methylation is not present or
529 not detected by the currently used algorithms.


530

531 **Table 1:** Baseline characteristics of SMA patients sequenced with Nanopore sequencing
532 with homozygous *SMN1* deletion and no c.859G>C variant in *SMN2*.

	2xSMN2	3xSMN2	4xSMN2	5xSMN2	Overall
Total	15	215	122	7	359
Sex					
Male	10 (66.7%)	94 (43.7%)	71 (58.2%)	6 (85.7%)	181 (50.4%)
Female	5 (33.3%)	121 (56.3%)	51 (41.8%)	1 (14.3%)	178 (49.6%)
SMA type					
Type 1	15 (100%)	30 (14.0%)	1 (0.8%)	0 (0%)	46 (12.8%)
Type 2	0 (0%)	138 (64.2%)	14 (11.5%)	0 (0%)	152 (42.3%)
Type 3	0 (0%)	43 (20.0%)	96 (78.7%)	5 (71.4%)	144 (40.1%)
Type 4	0 (0%)	0 (0%)	9 (7.4%)	1 (14.3%)	10 (2.8%)
Presymptomatic	0 (0%)	4 (1.9%)	2 (1.6%)	1 (14.3%)	7 (1.9%)
Age at onset (years)					
Mean (SD)	0.205 (0.153)	1.08 (0.987)	7.39 (9.45)	11.5 (6.23)	3.30 (6.35)
Median [Min, Max]	0.208 [0, 0.500]	0.917 [0, 9.50]	2.50 [0.458, 43.0]	12.5 [1.00, 19.0]	1.08 [0, 43.0]
Missing	1 (6.7%)	11 (5.1%)	13 (10.7%)	1 (14.3%)	26 (7.2%)
Age at sampling (years)					
Mean (SD)	3.57 (4.64)	21.9 (16.9)	35.5 (20.7)	31.2 (14.4)	25.9 (19.6)
Median [Min, Max]	1.86 [0.282, 18.5]	19.6 [0.0438, 64.2]	37.3 [0.189, 79.7]	25.0 [18.0, 52.3]	23.1 [0.0438, 79.7]

533

534




535

536 **Figure 2: DNA methylation in the *SMN2* gene can be determined by targeted bisulfite**
537 **sequencing.**

538 (A) Location of 18 amplicons, 15 of which were sequenced successfully (blue, a total of
539 ~6.6kb around *SMN2*). Orange indicates amplicons with insufficient coverage for further
540 analyses.

541 (B) Heatmap of DNA methylation percentage per CpG site determined with targeted bisulfite
542 sequencing. Each row represents one patient, each column represents one CpG site.
543 Hierarchical clustering with the ward.D2 method was performed on the rows. Patient
544 characteristics are shown left of the heatmap. Clustering of patients is mostly based on DNA
545 methylation in intron 1 and the 3'UTR.




546

547 **Figure 3: DNA methylation in *SMN2* is significantly associated with age at sampling.**

548 (A-B) Principal component analysis (PCA) of the methylation data used for statistical
 549 analysis, colored by sex (A) or age (B). Sex clusters overlap completely, whereas age group
 550 clusters overlap only partly.

551 (C-D) Differential methylation analysis for sex (C) and age at sampling (D) shown with
 552 volcano plots (n=359). Fifteen sites including collapsed sites, corresponding to 22 CpG sites
 553 in total, are significantly associated with age ($p_{adj} < 0.01$).

554 (E) Methylation percentage of all sites analyzed in the differential methylation analysis.
555 Differentially methylated sites from (D) are colored red. DNA methylation significantly
556 decreased with age in all tested sites in intron 1 and the 3'UTR, and several sites in the
557 promoter and lncRNA and DNA methylation at one site in the promoter significantly
558 increased with age. Sites that were collapsed for statistical analysis (see **Methods**) are
559 indicated with an asterisk (*).



560

561 **Figure 4: No association was found between *SMN2* DNA methylation and *SMN2* copy**
 562 **number, SMA type or treatment response in SMA patients.**

563 (A-B) Principal component analysis (PCA) of DNA methylation on *SMN2* determined by
 564 bisulfite sequencing, colored by *SMN2* copy number (A) or SMA type (B).

565 (C-D) Differential methylation analysis for *SMN2* copy number (n=359) (C) and SMA type
 566 (n=352) (D). No differentially methylated sites were found ($p_{adj} < 0.01$).

567 (E) Difference in HFMSE score (dHFMSE) 1.5 years after nusinersen treatment versus
 568 before nusinersen treatment in patients with three or four copies of *SMN2*, plotted against
 569 baseline HFMSE score.

570 (F) PCA of DNA methylation on *SMN2* determined by bisulfite sequencing, colored by
 571 treatment response group based on HFMSE after nusinersen treatment. Treatment response
 572 was divided as follows: Decrease: $dHFMSE \leq -3$; Stabilization: $-3 < dHFMSE < 3$; Increase:
 573 $dHFMSE \geq 3$.

574 (G) Differential methylation analysis for dHFMSE shown with volcano plots (n=111). No
 575 differentially methylated sites were found ($p_{adj} < 0.01$).

576

577 **References**

- 578 1. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al.
579 Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a
580 literature review. *Orphanet J Rare Dis.* 2017;12:124.
- 581 2. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and
582 characterization of a spinal muscular atrophy-determining gene. *Cell.* 1995;80:155–65.
- 583 3. Lefebvre S, Burlet P, Liu Q, Bertrand S, Clermont O, Munnich A, et al. Correlation
584 between severity and SMN protein level in spinal muscular atrophy. *Nat Genet.*
585 1997;16:265–9.
- 586 4. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene
587 regulates splicing and is responsible for spinal muscular atrophy. *Proc Natl Acad Sci.*
588 1999;96:6307–11.
- 589 5. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AHM, et al. A
590 Single Nucleotide Difference That Alters Splicing Patterns Distinguishes the SMA Gene
591 SMN1 From the Copy Gene SMN2. *Hum Mol Genet.* 1999;8:1177–83.
- 592 6. Calucho M, Bernal S, Alías L, March F, Venceslá A, Rodríguez-Álvarez FJ, et al.
593 Correlation between SMA type and SMN2 copy number revisited: An analysis of 625
594 unrelated Spanish patients and a compilation of 2834 reported cases. *Neuromuscul Disord.*
595 2018;28:208–15.
- 596 7. Wirth B. Spinal Muscular Atrophy: In the Challenge Lies a Solution. *Trends Neurosci.*
597 2021;44:306–22.
- 598 8. Wadman RI, Jansen MD, Stam M, Wijngaarde CA, Curial CAD, Medic J, et al. Intragenic
599 and structural variation in the SMN locus and clinical variability in spinal muscular atrophy.
600 *Brain Commun.* 2020;2:fcaa075.
- 601 9. Ramos DM, d'Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, et al. Age-
602 dependent SMN expression in disease-relevant tissue and implications for SMA treatment. *J*
603 *Clin Invest.* 2019;129:4817–31.
- 604 10. Wadman RI, Stam M, Jansen MD, Weegen Y van der, Wijngaarde CA, Harschnitz O, et
605 al. A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with
606 Spinal Muscular Atrophy and Healthy Controls. *PLOS ONE.* 2016;11:e0167087.
- 607 11. Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. *Nat*
608 *Rev Dis Primer.* 2022;8:1–16.
- 609 12. Scheijmans FEV, Cuppen I, van Eijk RPA, Wijngaarde CA, Schoenmakers MAGC, van
610 der Woude DR, et al. Population-based assessment of nusinersen efficacy in children with
611 spinal muscular atrophy: a 3-year follow-up study. *Brain Commun.* 2022;4:fcac269.
- 612 13. Costa-Roger M, Blasco-Pérez L, Cuscó I, Tizzano EF. The Importance of Digging into
613 the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. *Int J*
614 *Mol Sci.* 2021;22:9029.
- 615 14. d'Ydewalle C, Ramos DM, Pyles NJ, Ng S-Y, Gorz M, Pilato CM, et al. The Antisense
616 Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for
617 Spinal Muscular Atrophy. *Neuron.* 2017;93:66–79.

- 618 15. Saffari A, Kölker S, Hoffmann GF, Weiler M, Ziegler A. Novel challenges in spinal
619 muscular atrophy – How to screen and whom to treat? *Ann Clin Transl Neurol.* 2019;6:197–
620 205.
- 621 16. Chaytow H, Faller KME, Huang Y-T, Gillingwater TH. Spinal muscular atrophy: From
622 approved therapies to future therapeutic targets for personalized medicine. *Cell Rep Med.*
623 2021;2:100346.
- 624 17. Greenberg MVC, Bourc'his D. The diverse roles of DNA methylation in mammalian
625 development and disease. *Nat Rev Mol Cell Biol.* 2019;20:590–607.
- 626 18. Hauke J, Riessland M, Lunke S, Eyüpoglu IY, Blümcke I, El-Osta A, et al. Survival motor
627 neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease
628 severity and can be bypassed by histone deacetylase inhibition. *Hum Mol Genet.*
629 2009;18:304–17.
- 630 19. Cao Y, Qu Y, He S, Li Y, Bai J, Jin Y, et al. Association between SMN2 methylation and
631 disease severity in Chinese children with spinal muscular atrophy. *J Zhejiang Univ-Sci B.*
632 2016;17:76–82.
- 633 20. Wang J, Bai J, OuYang S, Wang H, Jin Y, Peng X, et al. Antisense oligonucleotides
634 targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy
635 cell lines and mouse model. *Hum Mol Genet.* 2022;31:1635–50.
- 636 21. Zheleznyakova GY, Voisin S, Kiselev AV, Sällman Almén M, Xavier MJ, Maretina MA, et
637 al. Genome-wide analysis shows association of epigenetic changes in regulators of Rab and
638 Rho GTPases with spinal muscular atrophy severity. *Eur J Hum Genet.* 2013;21:988–93.
- 639 22. Zheleznyakova GY, Nilsson EK, Kiselev AV, Maretina MA, Tishchenko LI, Fredriksson R,
640 et al. Methylation Levels of SLC23A2 and NCOR2 Genes Correlate with Spinal Muscular
641 Atrophy Severity. *PLOS ONE.* 2015;10:e0121964.
- 642 23. Zwartkruis MM, Elferink MG, Gommers D, Signoria I, Blasco-Pérez L, Costa-Roger M, et
643 al. Long-read sequencing identifies copy-specific markers of SMN gene conversion in spinal
644 muscular atrophy [Internet]. *medRxiv*; 2024 [cited 2024 Oct 2]. p. 2024.07.16.24310417.
645 Available from: <https://www.medrxiv.org/content/10.1101/2024.07.16.24310417v1>
- 646 24. Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA
647 methylation atlas of normal human cell types. *Nature.* 2023;613:355–64.
- 648 25. Chen X, Harting J, Farrow E, Thiffault I, Kasperaviciute D, Hoischen A, et al.
649 Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-
650 read PacBio HiFi sequencing. *Am J Hum Genet.* 2023;110:240–50.
- 651 26. Titcombe P, Murray R, Hewitt M, Antoun E, Cooper C, Inskip HM, et al. Human non-CpG
652 methylation patterns display both tissue-specific and inter-individual differences suggestive
653 of underlying function. *Epigenetics.* 2022;17:653–64.
- 654 27. Patil V, Ward RL, Hesson LB. The evidence for functional non-CpG methylation in
655 mammalian cells. *Epigenetics.* 2014;9:823–8.
- 656 28. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, et al. CTCF-
657 promoted RNA polymerase II pausing links DNA methylation to splicing. *Nature.*
658 2011;479:74–9.

- 659 29. Ong C-T, Corces VG. CTCF: an architectural protein bridging genome topology and
660 function. *Nat Rev Genet.* 2014;15:234–46.
- 661 30. Monteagudo-Sánchez A, Noordermeer D, Greenberg MVC. The impact of DNA
662 methylation on CTCF-mediated 3D genome organization. *Nat Struct Mol Biol.* 2024;31:404–
663 12.
- 664 31. Kulakovskiy IV, Vorontsov IE, Yevshin IS, Sharipov RN, Fedorova AD, Rumynskiy EI, et
665 al. HOCOMOCO: towards a complete collection of transcription factor binding models for
666 human and mouse via large-scale ChIP-Seq analysis. *Nucleic Acids Res.* 2018;46:D252–9.
- 667 32. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif.
668 *Bioinformatics.* 2011;27:1017–8.
- 669 33. Marasco LE, Dujardin G, Sousa-Luís R, Liu YH, Stigliano JN, Nomakuchi T, et al.
670 Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves
671 its therapeutic efficacy in spinal muscular atrophy. *Cell.* 2022;185:2057-2070.e15.
- 672 34. Luo R, Bai C, Yang L, Zheng Z, Su G, Gao G, et al. DNA methylation subpatterns at
673 distinct regulatory regions in human early embryos. *Open Biol.* 2018;8:180131.
- 674 35. McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, et al. Pan-cancer
675 genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.
676 *EBioMedicine.* 2019;43:127–37.
- 677 36. Zhang Q, Sun S, Xie Q, Wang X, Qian J, Yao J, et al. FAM81A Identified as a Stemness-
678 Related Gene by Screening DNA Methylation Sites Based on Machine Learning-Accessed
679 Stemness in Pancreatic Cancer. *Epigenomics.* 2022;14:569–88.
- 680 37. Malumbres M, Pérez de Castro I, Santos J, Fernández Piqueras J, Pellicer A.
681 Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with
682 its transcriptional regulation in primary lymphomas. *Oncogene.* 1999;18:385–96.
- 683 38. Maussion G, Yang J, Suderman M, Diallo A, Nagy C, Arnovitz M, et al. Functional DNA
684 methylation in a transcript specific 3'UTR region of TrkB associates with suicide.
685 *Epigenetics.* 2014;9:1061–70.
- 686 39. Fujii S, Shinjo K, Matsumoto S, Harada T, Nojima S, Sato S, et al. Epigenetic
687 upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes
688 tumorigenesis of lung squamous cell carcinoma. *Oncotarget.* 2016;7:81571–87.
- 689 40. Shen Z, Zhu L, Zhang C, Cui X, Lu J. Overexpression of BHLHE41, correlated with DNA
690 hypomethylation in 3'UTR region, promotes the growth of human clear cell renal cell
691 carcinoma. *Oncol Rep.* 2019;41:2137–47.
- 692 41. Koike Y, Sugai A, Hara N, Ito J, Yokoseki A, Ishihara T, et al. Age-related demethylation
693 of the TDP-43 autoregulatory region in the human motor cortex. *Commun Biol.* 2021;4:1–11.
- 694 42. Wang D, Jia Y, Zheng W, Li C, Cui W. Overexpression of eIF3D in Lung Adenocarcinoma
695 Is a New Independent Prognostic Marker of Poor Survival. *Dis Markers.*
696 2019;2019:6019637.
- 697 43. Mishra NK, Guda C. Genome-wide DNA methylation analysis reveals molecular
698 subtypes of pancreatic cancer. *Oncotarget.* 2017;8:28990–9012.

- 699 44. Krushkal J, Silvers T, Reinhold WC, Sonkin D, Vural S, Connelly J, et al. Epigenome-
700 wide DNA methylation analysis of small cell lung cancer cell lines suggests potential
701 chemotherapy targets. *Clin Epigenetics*. 2020;12:93.
- 702 45. Zou X, Ma W, Solov'yov IA, Chipot C, Schulten K. Recognition of methylated DNA
703 through methyl-CpG binding domain proteins. *Nucleic Acids Res*. 2012;40:2747–58.
- 704 46. Nanavaty V, Abrash EW, Hong C, Park S, Fink EE, Li Z, et al. DNA Methylation
705 Regulates Alternative Polyadenylation via CTCF and the Cohesin Complex. *Mol Cell*.
706 2020;78:752-764.e6.
- 707 47. Mitschka S, Mayr C. Context-specific regulation and function of mRNA alternative
708 polyadenylation. *Nat Rev Mol Cell Biol*. 2022;23:779–96.
- 709 48. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene Body Methylation
710 Can Alter Gene Expression and Is a Therapeutic Target in Cancer. *Cancer Cell*.
711 2014;26:577–90.
- 712 49. Padeken J, Methot SP, Gasser SM. Establishment of H3K9-methylated heterochromatin
713 and its functions in tissue differentiation and maintenance. *Nat Rev Mol Cell Biol*.
714 2022;23:623–40.
- 715 50. Lu AT, Fei Z, Haghani A, Robeck TR, Zoller JA, Li CZ, et al. Universal DNA methylation
716 age across mammalian tissues. *Nat Aging*. 2023;3:1144–66.
- 717 51. Signoria I, Zwartkruis MM, Geerlofs L, Perenthaler E, Faller KME, James R, et al.
718 Patient-specific responses to *SMN2* splice-modifying treatments in spinal muscular atrophy
719 fibroblasts. *Mol Ther - Methods Clin Dev*. 2024;101379.
- 720 52. Morita S, Noguchi H, Horii T, Nakabayashi K, Kimura M, Okamura K, et al. Targeted DNA
721 demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions.
722 *Nat Biotechnol*. 2016;34:1060–5.
- 723 53. Vojta A, Dobrinić P, Tadić V, Bočkor L, Korać P, Julg B, et al. Repurposing the CRISPR-
724 Cas9 system for targeted DNA methylation. *Nucleic Acids Res*. 2016;44:5615–28.
- 725 54. Wijngaarde CA, Stam M, Otto LAM, van Eijk RPA, Cuppen I, Veldhoen ES, et al.
726 Population-based analysis of survival in spinal muscular atrophy. *Neurology*.
727 2020;94:e1634–44.
- 728 55. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al.
729 Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N Engl J Med*.
730 2018;378:625–35.
- 731 56. Ewels P, Hüther P, Miller E, Sateesh_Perri, Spix N, bot nf-core, et al. nf-core/methylseq:
732 Huggy mollusc [Internet]. Zenodo; 2024 [cited 2024 Nov 17]. Available from:
733 <https://zenodo.org/records/10463781>
- 734 57. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
735 Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: [https://www.R-](https://www.R-project.org/)
736 [project.org/](https://www.R-project.org/)
- 737 58. Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2024 Nov 19]. Available
738 from: <https://cran.r-project.org/web/packages/pheatmap/index.html>

- 739 59. Lê S, Josse J, Husson F. FactoMineR: An R Package for Multivariate Analysis. *J Stat*
740 *Softw.* 2008;25:1–18.
- 741 60. Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate
742 Data Analyses [Internet]. 2020 [cited 2024 Nov 19]. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/factoextra/index.html)
743 [project.org/web/packages/factoextra/index.html](https://cran.r-project.org/web/packages/factoextra/index.html)
- 744 61. Crooks GE, Hon G, Chandonia J-M, Brenner SE. WebLogo: A Sequence Logo
745 Generator. *Genome Res.* 2004;14:1188–90.
- 746 62. Champely S, Ekstrom C, Dalgaard P, Gill J, Weibelzahl S, Anandkumar A, et al. pwr:
747 Basic Functions for Power Analysis [Internet]. 2020 [cited 2024 Nov 19]. Available from:
748 <https://cran.r-project.org/web/packages/pwr/index.html>
- 749 63. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. New York:
750 Routledge; 1988.
- 751 64. Hop PJ, Zwamborn RAJ, Hannon E, Shireby GL, Nabais MF, Walker EM, et al. Genome-
752 wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol
753 pathways in ALS. *Sci Transl Med.* 2022;14:eabj0264.
- 754 65. Zhang Q, Vallerga CL, Walker RM, Lin T, Henders AK, Montgomery GW, et al. Improved
755 precision of epigenetic clock estimates across tissues and its implication for biological
756 ageing. *Genome Med.* 2019;11:54.
- 757 66. Grant OA, Wang Y, Kumari M, Zabet NR, Schalkwyk L. Characterising sex differences of
758 autosomal DNA methylation in whole blood using the Illumina EPIC array. *Clin Epigenetics.*
759 2022;14:62.
- 760